Mercator Medical (FRA:MM2) Growth Rank: 1 (As of Aug. 07, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MM2 Mercator Medical SA FRA:MM2
61 GF Score
Price €12.12
GF Value €10.68
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Mercator Medical Growth Rank?

Mercator Medical FRA:MM2 +2.36% 61 Growth Rank is 1 as of Aug. 07, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates FRA:MM2 with a GF Score™ of 61/100 and a GF Value™ of €10.68 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Mercator Medical has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Mercator Medical Growth Rank Related Terms

FRA:MM2 vs ISRG, BDX, MDLN: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, Mercator Medical's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mercator Medical Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mercator Medical's Growth Rank distribution charts can be found below:

* The bar in red indicates where Mercator Medical's Growth Rank falls into.


FRA:MM2
61GF Score
Mercator Medical SA FRA:MM2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Mercator Medical (FRA:MM2) has a Growth Rank of 1 as of Aug. 07, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mercator Medical and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Mercator Medical's Growth Rank has ranged from 1.00 to 8.00.
Is Mercator Medical's Growth Rank too high?
Mercator Medical's current Growth Rank of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, Mercator Medical has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mercator Medical's Growth Rank compare to ISRG and BDX?
Mercator Medical's Growth Rank of 1 can be compared against companies in the Medical Devices & Instruments industry. Historically, Mercator Medical's own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mercator Medical and its competitors. Mercator Medical's current Growth Rank is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercator Medical stock overvalued right now?
Based on GuruFocus' analysis, Mercator Medical (FRA:MM2) is currently considered Modestly Overvalued. The stock's GF Value™ is €10.68, compared to a current price of €12.12 — trading 13.5% above its estimated fair value. The current Growth Rank is 1, which is 67% below median its 10-year median of 3.00. Mercator Medical's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Mercator Medical (FRA:MM2), the current Growth Rank is 1 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercator Medical (FRA:MM2) Overvalued in 2026?

Based on GuruFocus' analysis, Mercator Medical stock appears to be overvalued. The current stock price of €12.12 is trading 13.5% above its estimated GF Value™ of €10.68. GuruFocus considers Mercator Medical to be Modestly Overvalued.

Key valuation signals for FRA:MM2:

  • Growth Rank: 1 (67% below median its 10-year median of 3.00)
  • GF Value™: €10.68 vs. price of €12.12 (13.5% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the FRA:MM2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercator Medical Business Description

Other Exchanges MRC:Poland
Address Ulica H. Modrzejewska 30, Krakow, POL, 31-327
Mercator Medical SA produces and sells medical gloves and distributor of medical disposables. The company's products - mainly gloves, dressings, disposable clothing and surgical drapes. It operates in Europe and Russia.
61GF Score

Get the complete analysis for FRA:MM2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.12
Price
€10.68
GF Value